Loading clinical trials...
Loading clinical trials...
Background:Altered Toll-like receptor (TLR) expression levels and/or mutations in its signaling pathway (such as MyD88 mutation) contribute to the pathogenesis of lymphoproliferative disorders (LPD). ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hospices Civils de Lyon
NCT06549595 · Untreated Follicular Lymphoma
NCT03190928 · Follicular Lymphoma
NCT06191744 · Follicular Lymphoma (FL)
NCT06852638 · Renal Cancer, Renal Clear Cell Carcinoma, and more
NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions